Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: A randomized phase 2 clinical trial
JAMA Oncology Feb 23, 2018
Cremolini C, et al. - The activity and safety of cetuximab plus modified FOLFOXIRI (mFOLFOXIRI) were determined along with the role of maintenance cetuximab or bevacizumab in RAS and BRAF wild-type metastatic colorectal cancer (mCRC). The feasibility of a 4-month induction regimen of mFOLFOXIRI plus cetuximab was demonstrated. Moreover, this regimen provided relevant activity results, resulting in a high surgical resection rate.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries